Lyell Immunopharma Inc. (LYEL)
NASDAQ: LYEL
· Real-Time Price · USD
14.97
2.14 (16.68%)
At close: Sep 29, 2025, 3:59 PM
14.82
-1.00%
After-hours: Sep 29, 2025, 07:56 PM EDT
16.68% (1D)
| Bid | 12.67 |
| Market Cap | 287.59M |
| Revenue (ttm) | 60K |
| Net Income (ttm) | -331.4M |
| EPS (ttm) | -24.26 |
| PE Ratio (ttm) | -0.62 |
| Forward PE | -1.06 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 15 |
| Volume | 63,392 |
| Avg. Volume (20D) | 54,868 |
| Open | 12.84 |
| Previous Close | 12.83 |
| Day's Range | 12.78 - 14.97 |
| 52-Week Range | 7.65 - 30.40 |
| Beta | -0.20 |
| Ex-Dividend Date | n/a |
About LYEL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LYEL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LYEL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+19.31%
Lyell Immunopharma shares are trading higher after...
Unlock content with
Pro Subscription
10 months ago
+19.35%
Lyell Immunopharma shares are trading higher. The stock may be moving on continued strength after the company announced yesterday it will present clinical data from its Phase 1-2 trial of IMPT-314 CAR T-cell therapy for B-cell lymphoma at ASH 2024.
2 months ago · seekingalpha.com
Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program AdvancementLyell Immunopharma's LYL314 CAR-T therapy shows high, durable response rates in 3rd-line + Large B-Cell Lymphoma patients. The company has initiated a phase 3 trial for LYL314 in 3rd-line + LBCL follo...